FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
Contenu indisponible. Consultez la source originale.
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.